^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

DDX5 overexpression

i
Other names: DDX5, DEAD-Box Helicase 5, DEAD/H (Asp-Glu-Ala-Asp/His) Box Polypeptide 5 (RNA Helicase, 68kD), Probable ATP-Dependent RNA Helicase DDX5, DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 5, DEAD (Asp-Glu-Ala-Asp) Box Helicase 5, DEAD Box Protein 5, RNA Helicase P68, G17P1, HLR1, ATP-Dependent RNA Helicase DDX5, DEAD Box-5, HUMP68, HELR, P68
Entrez ID:
22d
ALKBH5 promotes T-cell acute lymphoblastic leukemia growth via m6A-guided epigenetic inhibition of miR-20a-5p. (PubMed, Exp Cell Res)
miR-20a-5p suppressed DDX5 transcription. In conclusion, ALKBH5-mediated m6A demethylation decreases DGCR8 binding to pri-miR-20a, thereby repressing miR-20a-5p expression and enhancing DDX5 expression, ultimately inhibiting T-ALL cell apoptosis and promoting proliferation.
Journal
|
DDX5 (DEAD-Box Helicase 5) • ALKBH5 (AlkB Homolog 5, RNA Demethylase) • MIR20A (MicroRNA 20a)
|
DDX5 overexpression
11ms
DDX5 Functions as a Tumor Suppressor in Tongue Cancer. (PubMed, Cancers (Basel))
The knockdown of DDX5 promotes, while the overexpression of DDX5 inhibits, tongue cancer proliferation, development, and cisplatin resistance...Specifically, the expression of DDX5 is associated with the reduced infiltration of M2 macrophages and increased infiltration of T cell clusters, which may contribute to anticancer effects in the tumor microenvironment. In this study, we establish DDX5 as a valuable prognostic biomarker and an important tumor suppressor in tongue cancer.
Journal
|
DDX5 (DEAD-Box Helicase 5)
|
DDX5 overexpression
|
cisplatin
12ms
AURKAIP1 actuates tumor progression through stabilizing DDX5 in triple negative breast cancer. (PubMed, Cell Death Dis)
Consequently, AURKAIP1 silencing suppressed the activity of Wnt/β-catenin signaling in a DDX5-dependent manner. Our study may primarily disclose the molecular mechanism by which AURKAIP1/DDX5/β-catenin axis modulated TNBC progression, indicating that AURKAIP1 might serve as a therapeutic target as well as a TNBC-specific biomarker for prognosis.
Journal
|
AURKA (Aurora kinase A) • DDX5 (DEAD-Box Helicase 5)
|
DDX5 overexpression
12ms
RNA helicase DDX5 modulates sorafenib sensitivity in hepatocellular carcinoma via the Wnt/β-catenin-ferroptosis axis. (PubMed, Cell Death Dis)
Conversely, overexpression of DDX5 in vivo enhances the anti-tumor efficacy of sorafenib by suppressing Wnt/β-catenin activation and induction of ferroptosis. Thus, DDX5 overexpression in combination with mTKIs is a promising therapeutic strategy for HCC.
Journal • IO biomarker
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • DDX5 (DEAD-Box Helicase 5) • DVL1 (Dishevelled Segment Polarity Protein 1)
|
DDX5 overexpression
|
sorafenib
over1year
The DEAD-box RNA helicase DDX5 (p68) and β-catenin: The crucial regulators of FOXM1 gene expression in arbitrating colorectal cancer. (PubMed, Biochim Biophys Acta Gene Regul Mech)
Thiostrepton delineated the effect of FOXM1 inhibition on cell proliferation and migration. Colony formation assay, migration assay, and cell cycle data reveal the importance of the DDX5 (p68)/β-catenin/FOXM1 axis in oncogenesis. Collectively, our study mechanistically highlights the regulation of FOXM1 gene expression by DDX5 (p68) and β-catenin in colorectal cancer.
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • DDX5 (DEAD-Box Helicase 5) • FOXM1 (Forkhead Box M1) • TCF4 (Transcription Factor 4)
|
DDX5 overexpression
|
thiostrepton (RSO-021)
2years
Investigation of androgen receptor-dependent alternative splicing has identified a unique subtype of lethal prostate cancer. (PubMed, Asian J Androl)
Overall, these results strongly suggest a nonclassical role of AR in mediating robust alternative RNA splicing in PCa. Moreover, AR-mediated alternative spicing contributes to aggressive PCa progression, where we identified a new subtype of lethal PCa defined by AR-dependent alternative splicing.
Journal
|
AR (Androgen receptor) • DDX5 (DEAD-Box Helicase 5) • KHDRBS1 (KH RNA Binding Domain Containing, Signal Transduction Associated 1)
|
DDX5 overexpression
2years
DDX5 mRNA-targeting Antisense Oligonucleotide as a new promising therapeutic in combating Castration-Resistant Prostate Cancer. (PubMed, Mol Ther)
The Heat Shock Protein 27 (Hsp27) has emerged as a principal factor of the Castration-Resistant Prostate Cancer (CRPC) progression, also, an Antisense Oligonucleotide (ASO) against Hsp27 (OGX-427 or Apatorsen) has been assessed in different clinical trials...We first present the interactions of DDX5 and the Ku70/80 heterodimer and the transcription factor IIH (TFIIH), thereby uncovering DDX5 roles in different DNA repair pathways. Collectively, our study highlights critical functions of DDX5 contributing to CRPC progression and provides preclinical proof-of-concept that a combination of ASO-directed DDX5 inhibition with a DNA damage-inducing therapy can serve as a highly potential novel strategy to treat CRPC.
Journal
|
DDX5 (DEAD-Box Helicase 5)
|
DDX5 overexpression
|
apatorsen (OGX-427)
over2years
RNA helicase DEAD-box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling. (PubMed, Hepatology)
These findings provide new mechanistic insight into the role of DDX5 in mTORC1 regulation and NASH progression, as well as suggest a number of new targets and a promising lead compound for therapeutic interventions against NASH.
Journal
|
TSC1 (TSC complex subunit 1) • DDX5 (DEAD-Box Helicase 5) • NLRP3 (NLR Family Pyrin Domain Containing 3)
|
DDX5 overexpression
over2years
FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy. (PubMed, Clin Transl Med)
DDX5 is a bona fide FL118 direct target and can act as a biomarker for predicting PDAC and CRC tumour sensitivity to FL118. This would greatly impact FL118 precision medicine for patients with advanced PDAC or advanced CRC in the clinic. FL118 may act as a 'molecular glue degrader' to directly glue DDX5 and ubiquitination regulators together to degrade DDX5.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MCL1 (Myeloid cell leukemia 1) • BIRC3 (Baculoviral IAP repeat containing 3) • BIRC5 (Baculoviral IAP repeat containing 5) • DDX5 (DEAD-Box Helicase 5) • XIAP (X-Linked Inhibitor Of Apoptosis)
|
KRAS mutation • MCL1 expression • DDX5 overexpression • BIRC5 mutation
|
FL118
over2years
Knockdown of KRAB domain-associated protein 1 suppresses the proliferation, migration and invasion of thyroid cancer cells by regulating P68/DEAD box protein 5. (PubMed, Bioengineered)
Moreover, activation of Wnt/β-catenin signaling retarded the anti-tumor activity of KAP-1 knockdown. In conclusion, the data in this study disclosed that KAP-1 silence helped to repress the cell proliferation, migration and invasion by degrading DDK5, so as to hinder the development of thyroid cancer.
Journal
|
DDX5 (DEAD-Box Helicase 5)
|
DDX5 overexpression